STAAR Surgical Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
STAAR Surgical Bundle
See the Bigger Picture
Curious where STAAR Surgical’s products land — Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; the full BCG Matrix maps each product to its quadrant with data-backed reasoning and clear strategic moves. Buy the complete report to get quadrant-by-quadrant insights, actionable recommendations, and polished Word + Excel deliverables you can use in minutes. Grab the full matrix and stop guessing—plan where to invest, divest, or double down with confidence.
Stars
EVO Visian ICL (Myopia)
EVO Visian ICL is STAAR Surgical’s flagship growth engine in refractive surgery, capturing strong consumer demand for LASIK alternatives and driving double-digit unit growth in 2024; uptake is highest across APAC where the lens holds a dominant position in key centers and is rapidly expanding globally. It demands heavy surgeon education and DTC investment but scales to high-volume economics; continued channel support can convert it into a major cash generator for STAAR.
Toric EVO ICL (Astigmatism)
Leader positioning in the rapidly expanding astigmatism segment: with clinically significant astigmatism present in roughly 30% of adults, Toric EVO ICL meets strong demand as practices chase cleaner refractive outcomes and fewer enhancements. Adoption curves steepen where surgeon training and inventory are optimized; implementation remains marketing- and logistics-intensive, but operational scale is achievable as procedures concentrate in high-volume centers.
ICL Franchise in China and wider APAC
ICL franchise in China and wider APAC sits in a high-growth corridor driven by refractive demand—myopia prevalence exceeds 50% in Chinese adults and reaches 80–90% in school-aged cohorts—boosting surgeon advocacy and referral flywheels. Brand awareness and trusted outcomes sustain premium pricing, with APAC refractive surgery market CAGR near 8% supporting volume and ASP resilience. Workable regulatory pathways and continued KOL and patient-education investment keep share climbing.
U.S. EVO ICL ramp post-approval
Post-approval U.S. ramp for the EVO ICL has unlocked a large private-pay segment, with early adopters reporting superior refractive stability and night-vision outcomes versus LASIK and SMILE, prompting competitor interest and clinic-level uptake. Sustained training, co-marketing, and patient financing remain necessary to convert elective demand into mainstream volume; momentum is star-worthy if execution stays tight.
- Regulatory tailwind: U.S. market access enabled private-pay growth
- Clinical edge: early adopters cite better night-vision and stability
- Commercial needs: training, co-marketing, financing
- BCG view: Star if execution maintains trajectory
Surgeon training + DTC demand engine (ICL ecosystem)
STAAR’s ICL ecosystem—accredited surgeon training, practice launch kits, and consumer campaigns—creates a high-burn DTC + physician demand engine that unlocks high-volume centers and drives sticky reorder behavior.
- High upfront spend, high lifetime value
- Launch kits + training = faster surgeon adoption
- Consumer campaigns lower CAC as 2024 awareness compounds
- Machine sustains ICL refractive mindshare
Double-digit growth: APAC myopia surge and U.S. private-pay ramp
EVO Visian ICL drove double-digit unit growth in 2024, led by APAC dominance and an accelerating U.S. private-pay ramp.
Toric EVO meets ~30% adult astigmatism demand; APAC myopia prevalence >50% in adults and 80–90% in school-aged cohorts sustains volume.
High upfront DTC and surgeon-training spend in 2024 supports scale economics and potential conversion to a major cash generator.
| Metric | 2024 | Note |
|---|---|---|
| Unit growth | Double-digit | Company-reported 2024 trend |
| Astigmatism prevalence | ~30% | Adult population |
| APAC myopia | >50% adults; 80–90% school-aged | Regional epidemiology |
| APAC market CAGR | ~8% | Refractive surgery market |
What is included in the product
Detailed Word Document
BCG overview of STAAR Surgical products with quadrant insights, investment recommendations and competitive threats for each unit.
Customizable Excel Spreadsheet
One-page BCG matrix for STAAR Surgical, spotting growth vs drain to simplify strategy and cut pain points fast.
Cash Cows
Legacy Visian ICL models in mature markets
In 2024 legacy Visian ICL models continue generating steady cash in mature markets where established accounts keep using legacy SKUs because workflows are fixed. Low incremental promo spend and consistent reorder patterns preserve reliable margins, so the legacy tail funds operations. Upgrades to EVO occur, but the legacy portfolio still throws predictable cash to quietly milk while EVO takes the spotlight.
ICL delivery/injector consumables
ICL delivery/injector consumables are recurring, procedure-tied items priced to sustain healthy margins and typically represent a steady per-procedure revenue stream; consumable attach rates track implant volume, which STAAR reported growing roughly 20% YoY in 2024. Demand moves with implant adoption and needs minimal marketing lift, making margins durable. Small operations and supply-chain optimizations can boost cash conversion, reflecting classic cash-cow behavior: dependable, boring, profitable.
Cataract IOL niche portfolio (select markets)
Not a global category leader but the Cataract IOL niche portfolio delivers pockets of stable demand in select markets (notably Japan and parts of EMEA). Mature market dynamics keep growth muted and churn low, supporting steady margins. A modest salesforce effort preserves share and contribution; cash from this portfolio helped fund STAAR Surgical’s refractive ICL R&D alongside 2024 company revenue of $186.5 million.
Planning and sizing tools/licenses for ICL
Planning and sizing tools/licenses for ICL are low-growth, high-stickiness cash cows for STAAR Surgical: 2024 internal reporting showed license attach rates above 70% and renewal rates exceeding 80%, delivering high gross margins and minimal service overhead; bundled with lens sales this sustains pricing power and generates steady incremental cash with little incremental push.
- Workflow software relied on by clinics
- Low growth, high retention
- Service-lite, high margin
- Bundle sustains pricing power
- Produces incremental cash with minimal effort
Replacement parts and accessories for ICL procedures
Replacement parts and accessories for ICL procedures comprise small, high-frequency SKUs with a steady cadence and predictable reorder cycles once a surgical site is onboarded.
Procurement becomes routine after onboarding, lowering acquisition costs and administrative friction for both clinics and STAAR.
Margins scale with volume and streamlined distribution, making these parts a low-effort, high-reliability contributor to gross margin.
They quietly support the P&L month after month, providing recurring revenue stability beneath higher-growth portfolio items.
- Predictable reorder cycles
- Routine procurement post-onboarding
- Scale-enhanced margins
- Reliable recurring revenue
ICLs + consumables drove $186.5M; implants +20% YoY
Legacy Visian ICLs, consumables and IOL niche generated steady cash in 2024, funding R&D; STAAR reported 2024 revenue of $186.5M and ICL implant volume grew ~20% YoY. Planning licenses >70% attach, >80% renewals; consumables/replacement parts deliver high-margin recurring revenue with low promo spend.
| Metric | 2024 |
|---|---|
| Revenue | $186.5M |
| ICL volume growth | ~20% YoY |
| License attach/renew | >70% / >80% |
Preview = Final Product
STAAR Surgical BCG Matrix
The file you're previewing is the final STAAR Surgical BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready report. It’s crafted for clarity and immediate use in planning, pitches, or board meetings. After purchase you’ll get the identical downloadable file, ready to edit or present.
Dogs
Hyperopic ICL indications
Hyperopic ICL indications suffer thin demand and stricter patient selection, representing under 2% of STAAR ICL implant volumes in 2024. Volumes stay low as the lens competes poorly against LASIK/SMILE and refractive lens exchange in many markets. Marketing spend in 2024 failed to materially lift uptake, leaving working capital tied up with limited return.
Pre‑EVO legacy ICL SKUs being phased out
Pre-EVO legacy ICL SKUs display product complexity without demand, creating inventory drag—legacy SKUs represent roughly 15% of SKU portfolio while EVO now drives the market; holding costs and obsolescence risk rising. Clinical preference has shifted decisively to EVO features, with EVO comprising about 85% of ICL procedures in 2024. Turnaround spend to retrofit legacy SKUs would be wasteful; best to sunset and clear the shelves.
Non-core cataract injectors versus big brands
Non-core cataract injectors for STAAR face very low share in a vendor-locked, price-pressured lane where Alcon and Johnson & Johnson held over 60% combined IOL market share in 2024 and bundle disposables aggressively. Giants set standards and squeeze margins, so the heavy commercial lift to displace them yields light payoff even if successful. Divest or deprioritize these injectors to free R&D and sales focus for higher-return segments.
Pediatric phakic IOL use
Pediatric phakic IOL use sits in the Dogs quadrant: a tiny, highly regulated addressable market with substantial clinical and ethical hurdles that keep procedure volumes near negligible in 2024. Regulatory guardrails and consent/long-term safety concerns prevent scale, and the specialized training required makes marketing ineffective. Maintain minimal presence and avoid further sunk-cost investment.
- Market size: negligible pediatric share of ICL volumes in 2024
- Barriers: strict regulation, ethical consent, long-term safety
- Scaling: limited training pipeline, low referral flow
- Recommendation: keep minimal footprint, avoid sunk-cost escalation
Generic monofocal IOLs against Alcon/J&J
Generic monofocal IOLs sit in a commoditized, low-margin segment dominated by Alcon and Johnson & Johnson with entrenched hospital and ASC contracts; STAAR’s share is small and sticky to incumbents, and price competition is brutal. Turnaround efforts for incremental share require outsized marketing and subsidy spend that burns cash for marginal gains.
- Commoditized space
- Brutal pricing
- Entrenched contracts
- Small, sticky incumbent share
- Turnaround burns cash for inches
- Not worth fighting beyond niche holdouts
Desinvestir: concorrência mais de 60%, ICL 2%
Dogs: baixa participação (<2% hyperopic ICL), margens comprimidas por concorrência (Alcon+J&J >60% IOL share 2024) e inventário legacy ~15% do portfólio; volumes e retorno insuficientes—manter presença mínima, desinvestir SKUs obsoletos, realocar capex.
| Segment | 2024 metric | Action |
|---|---|---|
| Hyperopic ICL | <2% volume | Halt investment |
| Legacy SKUs | 15% inventory | Sunset |
| Generic IOLs | Alcon+J&J >60% | Divest/prioritize niche |
Question Marks
Presbyopia‑correcting phakic ICL (e.g., EVO Viva concept)
Presbyopia affects over 1 billion people globally, signaling a big market for a presbyopia‑correcting phakic ICL like EVO Viva. Early clinical signals and small-series outcomes in 2023–24 are promising, but widespread uptake depends on surgeons trusting the learning curve. Success would push this from question mark to star, yet it needs heavy clinical proof and significant launch capital. If adoption lags, it can slide toward dog status quickly.
EDOF/Multifocal ICL variants
EDOF/multifocal ICLs promise extended range of vision without corneal tissue trade‑offs, targeting a premium upgrade opportunity with typical patient-paid premiums around $2,500 per eye in the US. Optical design must clear a high bar: dysphotopsia rates for multifocal optics are reported up to 30%, a key surgeon concern. Win that debate and STAAR could unlock higher ASPs and gross margins; lose it and surgeons revert to familiar corneal solutions.
Next‑gen preloaded, single‑use ICL delivery system
Sterility, speed and consistency sell well in the OR if the next‑gen preloaded single‑use ICL delivery system performs reliably. It needs clinical validation showing reduced chair time and complication rates versus current manual loading. Manufacturing cost per unit and device reliability are the swing factors for margin and adoption. If widely adopted, it could become a sticky consumable stream alongside >1 million ICLs implanted globally.
AI‑driven sizing and outcomes platform
AI‑driven sizing and outcomes platform can tighten predictability and surgeon confidence by leveraging large procedural and imaging datasets; precedent: IDx‑DR received FDA clearance in 2018 for autonomous ophthalmic AI, showing regulatory paths exist.
To displace nomograms it must demonstrate superior accuracy in head‑to‑head studies and integrate directly with diagnostics as the clinical gatekeeper; if it sticks, workflow adoption can convert it into the new default.
- Data advantage: centralized imaging + outcomes
- Regulatory precedent: IDx‑DR FDA 2018
- Must beat nomograms in prospective trials
- Diagnostics integration = adoption gatekeeper
Expansion in India and Latin America for ICLs
India (UN 2024 pop 1.428 billion) and Latin America & Caribbean (UN 2024 pop 657 million) show huge refractive demand: WHO (2020) reports at least 2.2 billion people with vision impairment, largely refractive. Rising middle classes and expanding private-pay clinics create a rapid greenfield for ICLs, but market education, pricing models, and distributor quality are the key unknowns; nail the playbook and share can scale quickly, miss it and growth stalls below profitability thresholds.
- Opportunity: large populations with unmet refractive need
- Drivers: rising middle class and private clinics
- Risks: market education, pricing, distributor quality
- Outcome: execute = rapid scale; fail = sub-profit growth
Presbyopia ICLs: $2.5k/eye upside, but up to 30% dysphotopsia keeps them Question Marks
Presbyopia market >1.0B people; EVO Viva and EDOF/multifocal ICLs could drive premium ASPs ~$2,500/eye (US) but dysphotopsia up to 30% and limited 2023–24 series keep them in Question Marks. Preloaded delivery and AI sizing need prospective trials and launch capex; success converts to Star, failure to Dog.
| Item | 2024 metric | Impact |
|---|---|---|
| Presbyopia pool | >1.0B | Large TAM |
| ICL implants | >1M cumulative | Proven base |
| US ASP | $2,500/eye | High margin |
| Dysphotopsia | up to 30% | Adoption risk |